Recent evidence suggests that adult bone marrow stem cells reduce tissue damage and promote repair following CNS ischemic injury. Since granulocyte-colony stimulating factor (G-CSF) mobilizes hematopoietic stem cells to the circulating compartment, here we tested whether administration of this drug modifies the outcome of a permanent occlusion of the middle cerebral artery in adult mice. To elucidate the behavior and fate of bloodborne cells in the ischemic brain, we produced chimeric animals, in which hematopoietic derivatives are genetically tagged. G-CSF administration enhances the proliferation of microglia in the uninjured CNS but has no effect on the amount of hematopoietic cells that infiltrate the ischemic tissue and on the size of the lesion. The blood-borne elements acquire different mesodermal identities but fail to adopt neural phenotypes, even though they occasionally fuse with Purkinje neurons. These results indicate that G-CSF treatment does not exert a significant beneficial effect on the ischemic injury.
Introduction
Granulocyte-colony stimulating factor (G-CSF) is a hematopoietic growth factor that stimulates proliferation and specification of neutrophil precursors (Morrison et al., 1997; Wright et al., 2001 ) and induces their large-scale mobilization from bone marrow (BM) to the peripheral blood (Levesque et al., 2003; Zou et al., 2004; Katayama et al., 2006) . Because of these properties, G-CSF has been widely used in clinical practice to treat neutropenia induced by chemotherapy, or in the case of BM transplantation (Welte et al., 1996) . Recent studies highlighted the efficacy of G-CSF in animal models of cerebral ischemia, reporting significant reduction of infarct size and improved functional recovery (Minnerup et al., 2008; Sevimli et al., 2009; Zhang et al., 2009 ). The beneficial effects of G-CSF have been attributed to different concurrent mechanisms, including antiapoptotic activity (Schäbitz et al., 2003; Schneider et al., 2005) , immunomodulation (von Aulock et al., 2004) , stimulation of neurogenesis (Schneider et al., 2005; Kawada et al., 2006; Diederich et al., 2009) , and angiogenesis (Lee et al., 2005) . These phenomena have been related to direct effects of G-CSF on neural cells or to enhanced colonization of ischemic regions by hematopoietic stem cells (HSCs) (Schäbitz and Schneider, 2007) . The latter cells may produce and release molecules endowed with neuroprotective or neurotrophic activity (Schäbitz and Schneider, 2007; Hokari et al., 2009 ) but could also contribute directly to nervous tissue repair by adopting local phenotypes (Brazelton et al., 2000; Mezey et al., 2000) or fusing with damaged neurons (Magrassi et al., 2007) .
The beneficial effects of G-CSF have been consistently observed following transient cerebral ischemia. Nevertheless, a dose-dependent expansion of cortical atrophy, associated with severe functional defects, has been reported following G-CSF administration in a model of permanent ligation of the middle cerebral artery (MCA) (Taguchi et al., 2007) . These negative outcomes have been attributed to an exaggerated inflammatory response, consequent to the enhanced G-CSF-induced infiltration of the infarct region by hematopoietic cells.
In spite of such contrasting reports, and considering their relevance for a potential use of G-CSF in the clinical treatment of stroke, little is known about the behavior and fate of blood-borne cells that colonize the ischemic brain following G-CSF stimulation and the consequent effects on ischemic injury. To address these issues, here we evaluated the effect of G-CSF application following permanent occlusion of the medial cerebral artery (MCAo). In this context, to relate the effects of G-CSF administration to the mobilization of hematopoietic elements and to the extension of ischemic brain damage, we prepared chimeric mice in which blood cells had been tagged by enhanced Green Fluorescent Protein (eGFP) expression. 
